Intra-articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: A pilot study

Clinical and Experimental Rheumatology

Volumn 22, Issue 3, 2004, Pages 300-306

  Berg, Per ^a   Olsson, Ulf ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Q Med AB   (Sweden)

Author keywords

Hip; Injections; Intra articular; Non animal stabilised hyaluronic acid; Osteoarthritis

Indexed keywords

ANALGESIC AGENT; DUROLANE; HYALURONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; FEMALE; HIP OSTEOARTHRITIS; HUMAN; JOINT STIFFNESS; MALE; MEDICAL ASSESSMENT; OPEN STUDY; OUTCOMES RESEARCH; PAIN ASSESSMENT; PHYSICAL CAPACITY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SINGLE DRUG DOSE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEALTH STATUS; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; PILOT PROJECTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 2342520122     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. GARDNER D: The nature and causes of osteoarthrosis. Br Med J (Clin Res Ed) 1983; 286: 418-24.
2. HOWELL D: Pathogenesis of osteoarthritis. Am J Med 1986; 80: 24-8.
3. CUNNINGHAM L, KELSEY JL: Epidemiology of musculoskeletal impairments and associated disability. Am J Pub Health 1984; 74: 574-9.
4. KRAMER JS, YELIN EH, EPSTEIN WV: Social and economic impacts of four musculoskeletal conditions. A study using national community-based data. Arthritis Rheum 1983; 26: 901-7.
5. LAWRENCE RC, HELMICK CG, ARNETT FC et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-99.
6. MARCH LM, BACHMEIER CJ: Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol 1997; 11: 817-34.
7. HINTON R, MOODY RL, DAVIS AW, THOMAS SF: Osteoarthritis: diagnosis and therapeutic considerations. Am Fam Physician 2002; 65: 841-8.
8. BELL GM, SCHNITZER TJ: Cox-2 inhibitors and other nonsteroidal anti-inflammatory drugs in the treatment of pain in the elderly. Clin Geriatr Med 2001; 17: 489-502, vi.
9. GRIFFIN MR, RAY WA, SCHAFFNER W: Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359-63.
10. RAY WA, STEIN CM, DAUGHERTY JR, HALL K, ARBOGAST PG GRIFFIN MR: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-3.
11. ZHAO SZ, REYNOLDS MW, LEJKOWITH J, WHELTON A, ARELLANO FM: A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001; 23: 1478-91.
12. HOCHBERG MC, ALTMAN RD, BRANDT KD et al.: Guidelines for the medical management of osteoarthritis: part II: osteoarthritis of the knee. Arthritis Rheum 1995; 38: 1541-6.
13. KIRWAN K: Is there a place for intra-articular hyaluronate in osteoarthritis of the knee ? Knee 2001; 8: 93-101.
14. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines: Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 1905-15.
15. PEYRON JG: Intrarticular hyaluronan injections in the treatment of osteoarthritis: state of the art review. J Rheumatol 1993; 20 (Suppl. 39): 10-15.
16. LINDQVIST U, TOMACHEV V, KAIREMO K, ASTROM G, JONSSON E, LUNDQVIST H: Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet 2002; 41: 603-13.
17. ADAMS ME: An analysis of clinical studies of the use of cross-linked hyaluronan, hylan, in the treatment of osteoarthritis. J Rheumatol 1993; 20 (Suppl. 39): 16-18.
18. ÅKERMARK C, BERG P, BJÖRKMAN A MALM P: Non-animal stabilised hyaluronic acid in the treatment of osteoarthritis of the knee - a tolerability study. Clin Drug Invest 2002; 22: 157-66.
19. ALTMAN R, ALARCON G, APPELROUTH D et al.: The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34: 505-14.
20. KELLGREN JH, LAWRENCE JS: Radiologic assessment of osteoarthritis. Ann Rheum Dis 1957; 16: 494-501.
21. DOUGADOS M, LECLAIRE P, Van der HEIJDE D, BLOCH DA, BELLAMY N, ALTMAN RD: Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 2000; 8: 395-403.
22. BRAGANTINI A, MOLINAROLI F: A pilot clinical evaluation of the treatment of hip osteoarthritis with hyaluronic acid. Curr Ther Res 1994; 55: 319-330.
23. LANZOTTI SB, MACHADO MB, NASCIMENTO RA et al.: Intra-articular sodium hyaluronate in unilateral coxofemural osteoarthritis treatment. Arthritis Rheum 2000; 43 (Suppl.): 336.
24. CONROZIER T, BERTIN P, MATHIEU P et al.: Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open-label, multicentre, pilot study. Clin Exp Rheumatol 2003; 21: 605-10.
25. BROCQ O, TRAN G, BREUIL V, GRISOT C, FLORY P EULLER-ZIEGLER L: Hip osteoarthritis: short-term efficacy and safety of viscosupplementation by hylan G-F 20. An open-label study in 22 patients. Joint Bone Spine 2002; 69: 388-91.